MIM
TCRR

MetLife Investment Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

MetLife Investment Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,591
Closed -$98.6K – 2579
2021
Q3 		$98.6K Hold
11,591
– – ﹤0.01% 2445
2021
Q2 		$190K Hold
11,591
– – ﹤0.01% 2199
2021
Q1 		$256K Hold
11,591
– – ﹤0.01% 1912
2020
Q4 		$359K Hold
11,591
– – ﹤0.01% 1653
2020
Q3 		$236K Buy
11,591
+3,380
+41% +$59.3K ﹤0.01% 1764
2020
Q2 		$126K Buy
+8,211
New +$94.7K ﹤0.01% 2146

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MetLife Investment Management's TCRR Position: Q4 2021 in Review

MetLife Investment Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 11,591 shares — an estimated $98.6K sold.

MetLife Investment Management first reported a position in TCRR in Q2 2020 and held it in 6 quarters. The position peaked at $359K in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • MetLife Investment Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 11,591 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $98.6K.
  • MetLife Investment Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 6 quarters.
  • MetLife Investment Management's TCR2 Therapeutics Inc. Common Stock position peaked at $359K in Q4 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.